Relacorilant, a cortisol modulator from Corcept Therapeutics Inc., produced new and strong phase III results in treating platinum-resistant ovarian cancer. The company also has relacorilant in studies ...
Peter Marks’ March 28 letter giving one week’s notice of his resignation as director of the U.S. FDA’s Center for Biologics Evaluation and Research (CBER) is sending more ripples of uncertainty ...
Capricor Therapeutics, Inc.’s CAPR share price has dipped by 14.62%, which has investors questioning if this is right time to ...
The Royal Observer on MSN11h
Meghan Markle Broke a Royal Tradition With Her Outfit Choice At Prince Louis' ChristeningAmerican-born Meghan Markle was never a fan of royal protocols, and old pictures and videos from her time across the pond ...
The New Voice of Ukraine on MSN16h
New Bucha memorial to capture horror and resilience of Russian occupationThe Urban Design team, led by Stanyslav Demin, won the architectural competition and will be responsible for the construction ...
Defeat Duchenne Canada, the country's leading funder of Duchenne muscular dystrophy (DMD) research, is set to begin accepting innovative research proposals as of March 31, 2025. They are seeking ...
From April 1, 2025, the higher TDS rate for non-filers (as per Section 206AB) will not apply under Section 194-IA ...
Keros Therapeutics (KROS) announced initial topline results from the Phase 1 clinical trial of KER-065 in healthy volunteers. Topline results ...
Trial achieved key objectives for safety, tolerability, pharmacokinetics and pharmacodynamicsClinical data from this trial, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback